Mayne Pharma Group Ltd (MYX.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 06/30
| 06-2020 | 06-2019 | 06-2018 | 06-2017 | 06-2016 | |
| Sales | 456,601 | 523,958 | 529,141 | 571,737 | 266,190 |
| Cost of Goods | 231,487 | 222,598 | 266,257 | 256,834 | 98,914 |
| Gross Profit | 225,114 | 301,360 | 262,884 | 314,903 | 167,276 |
| Operating Expenses | 245,342 | 278,917 | 229,112 | 201,534 | 119,162 |
| Operating Income | -20,228 | 22,443 | 33,772 | 113,369 | 48,114 |
| Interest Expense | 31,542 | 17,444 | 17,247 | 11,481 | 2,438 |
| Other Income | -83,597 | -358,716 | -183,312 | 14,047 | 4,161 |
| Pre-tax Income | -135,367 | -353,717 | -166,787 | 115,935 | 49,837 |
| Income Tax | -40,832 | -69,966 | -32,530 | 29,909 | 15,314 |
| Net Income Continuous | -94,535 | -283,751 | -134,257 | 86,026 | 34,523 |
| Minority Interests | 1,746 | 2,885 | 273 | 2,541 | 2,832 |
| Net Income | $-92,789 | $-280,866 | $-133,984 | $88,567 | $37,355 |
| EPS Basic Total Ops | -1.21 | -3.81 | -1.83 | 1.24 | 0.95 |
| EPS Basic Continuous Ops | -1.21 | -3.81 | -1.83 | 1.24 | 0.95 |
| EPS Diluted Total Ops | -1.21 | -3.81 | -1.83 | 1.21 | 0.92 |
| EPS Diluted Continuous Ops | -1.21 | -3.81 | -1.83 | 1.21 | 0.92 |
| EBITDA(a) | $-19,264 | $-241,776 | $-69,657 | $201,084 | $73,652 |